Johnson & Johnson spent $900 million to jointly develop a new anticancer drug, imecta, with Geron

Source: on November 14, 2014, as the saying goes in the health newspaper, "wine is not afraid of alley depth", it is more suitable to be used in today's biomedical industry After germon's new anticancer drug, imecta, was approved by the FDA for further clinical research, the pharmaceutical giant Johnson & Johnson announced to invest about 935 million US dollars in the new drug development process Under the agreement, Johnson & Johnson will first pay $35 million in upfront investment and add up to $900 million in milestone funds as appropriate, in accordance with the agreement between the two parties The news also boosted Geron's share price Imecta is mainly used to treat leukemia After Johnson & Johnson joined in, Geron plans to carry out further phase II clinical research on the treatment of myelofibrosis and myelodysplastic syndrome with this drug This work is expected to begin in 2015 In recent years, Johnson & Johnson no longer focuses on its own R & D department, but has reached many cooperation agreements with many small and medium-sized biomedical companies In addition to germon's imestat, the company also participated in the development of ibrutinib, a new leukemic drug, and daratumumab, a new drug of genmab These agreements also make the company's development strength further developed For Geron, this time, Johnson & Johnson extended an olive branch to itself In the past 20 years, Geron has not found its proper position It wasn't until 2011 that the company finally decided to position itself as a stem cell technology company and focus on cancer therapy research Before imes, however, some of the company's research was frequently frustrated The cooperation with Johnson & Johnson undoubtedly enhanced the confidence of investors to a great extent.